



Commercial/Healthcare Exchange PA Criteria Effective: May 12, 2022

Prior Authorization: Seglentis

Products Affected: Seglentis (celecoxib/tramadol) oral tablet

Medication Description: SEGLENTIS is indicated for the management of acute pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Celecoxib is a NSAID with analgesic, anti-inflammatory, and antipyretic properties. Celecoxib is believed to inhibit prostaglandin synthesis, primarily via inhibition of cyclooxygenase-2 (COX-2). Its mode of action may be due to a decrease of prostaglandins in peripheral tissues. Tramadol is an opioid agonist and inhibitor of norepinephrine and serotonin re-uptake. Its mode of action is believed to be due to both binding to mu-opioid receptors and weak inhibition of re-uptake of norepinephrine and serotonin

Covered Uses: Management of acute pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate

Exclusion Criteria:

1. Coronary Artery Bypass Graft (CABG) Surgery
2. Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
3. Known or suspected gastrointestinal obstruction, including paralytic ileus
4. Previous hypersensitivity (anaphylactic reactions and serious skin reactions) to tramadol, opioids, celecoxib, sulfonamide or any other component of the product
5. Significant respiratory depression
6. Concurrent use of monoamine oxidase inhibitors (MAOIs) or use within the last 14 days
7. History of Asthma, urticaria or other allergic type reactions after taking aspirin or other NSAIDs.

Required Medical Information:

1. Diagnosis
2. Previous therapies tried and failed

Prescriber Restriction: None

Age Restriction:

1. 12 years and older; **OR**
2. Patient must be 18 years and older if being used for post-operative management of pain in tonsillectomy and/or adenoidectomy

Coverage Duration: 12 months

Other Criteria:

Initial Approval Criteria

May 2022



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.



1. **Acute Pain.** Approve if the patient meets all of the following:
 - A. Patient has tried and failed, or is intolerant to **THREE** other non-opioid analgesics (such as meloxicam or ibuprofen); **AND**
 - B. Patient has tried and failed generic celecoxib and tramadol use in combination

References:

1. Seglentis™ [package insert]. Montgomery, AL, Kowa Pharmaceuticals America, Inc. Updated October 2021. Accessed April 8th, 2022.

Policy Revision history

| Rev # | Type of Change | Summary of Change | Sections Affected | Date |
|-------|----------------|-------------------|-------------------|-----------|
| 1 | New Policy | New Policy | All | 5/12/2022 |